The Flavonoid Isoliquiritigenin Reduces Lung Inflammation and Mouse Morbidity during Influenza Virus Infection.
Identifieur interne : 000D00 ( Main/Exploration ); précédent : 000C99; suivant : 000D01The Flavonoid Isoliquiritigenin Reduces Lung Inflammation and Mouse Morbidity during Influenza Virus Infection.
Auteurs : Hussein Traboulsi [Canada] ; Alexandre Cloutier [Canada] ; Kumaraswamy Boyapelly [Canada] ; Marc-André Bonin [Canada] ; Éric Marsault [Canada] ; André M. Cantin [Canada] ; Martin V. Richter [Canada]Source :
- Antimicrobial agents and chemotherapy [ 1098-6596 ] ; 2015.
Descripteurs français
- KwdFr :
- Animaux, Anti-inflammatoires (pharmacologie), Antiviraux (pharmacologie), Cellules épithéliales (), Cellules épithéliales (immunologie), Cellules épithéliales (virologie), Chalcones (pharmacologie), Charge virale (), Chimiokine CCL5 (génétique), Chimiokine CCL5 (immunologie), Facteur de nécrose tumorale alpha (génétique), Facteur de nécrose tumorale alpha (immunologie), Humains, Infections à Orthomyxoviridae (anatomopathologie), Infections à Orthomyxoviridae (immunologie), Infections à Orthomyxoviridae (traitement médicamenteux), Infections à Orthomyxoviridae (virologie), Interféron gamma (génétique), Interféron gamma (immunologie), Interleukine-1 bêta (génétique), Interleukine-1 bêta (immunologie), Interleukine-6 (génétique), Interleukine-6 (immunologie), Lignée cellulaire, Lymphocytes T CD8+ (), Lymphocytes T CD8+ (immunologie), Lymphocytes T CD8+ (virologie), Pneumopathie infectieuse (anatomopathologie), Pneumopathie infectieuse (immunologie), Pneumopathie infectieuse (traitement médicamenteux), Pneumopathie infectieuse (virologie), Poumon (), Poumon (anatomopathologie), Poumon (immunologie), Poumon (virologie), Récepteur PPAR gamma (génétique), Récepteur PPAR gamma (immunologie), Régulation de l'expression des gènes, Réplication virale (), Souris, Souris de lignée C57BL, Sous-type H1N1 du virus de la grippe A (), Sous-type H1N1 du virus de la grippe A (croissance et développement), Transduction du signal.
- MESH :
- anatomopathologie : Infections à Orthomyxoviridae, Pneumopathie infectieuse, Poumon.
- croissance et développement : Sous-type H1N1 du virus de la grippe A.
- génétique : Chimiokine CCL5, Facteur de nécrose tumorale alpha, Interféron gamma, Interleukine-1 bêta, Interleukine-6, Récepteur PPAR gamma.
- immunologie : Cellules épithéliales, Chimiokine CCL5, Facteur de nécrose tumorale alpha, Infections à Orthomyxoviridae, Interféron gamma, Interleukine-1 bêta, Interleukine-6, Lymphocytes T CD8+, Pneumopathie infectieuse, Poumon, Récepteur PPAR gamma.
- pharmacologie : Anti-inflammatoires, Antiviraux, Chalcones.
- traitement médicamenteux : Infections à Orthomyxoviridae, Pneumopathie infectieuse.
- virologie : Cellules épithéliales, Infections à Orthomyxoviridae, Lymphocytes T CD8+, Pneumopathie infectieuse, Poumon.
- Animaux, Cellules épithéliales, Charge virale, Humains, Lignée cellulaire, Lymphocytes T CD8+, Poumon, Régulation de l'expression des gènes, Réplication virale, Souris, Souris de lignée C57BL, Sous-type H1N1 du virus de la grippe A, Transduction du signal.
English descriptors
- KwdEn :
- Animals, Anti-Inflammatory Agents (pharmacology), Antiviral Agents (pharmacology), CD8-Positive T-Lymphocytes (drug effects), CD8-Positive T-Lymphocytes (immunology), CD8-Positive T-Lymphocytes (virology), Cell Line, Chalcones (pharmacology), Chemokine CCL5 (genetics), Chemokine CCL5 (immunology), Epithelial Cells (drug effects), Epithelial Cells (immunology), Epithelial Cells (virology), Gene Expression Regulation, Humans, Influenza A Virus, H1N1 Subtype (drug effects), Influenza A Virus, H1N1 Subtype (growth & development), Interferon-gamma (genetics), Interferon-gamma (immunology), Interleukin-1beta (genetics), Interleukin-1beta (immunology), Interleukin-6 (genetics), Interleukin-6 (immunology), Lung (drug effects), Lung (immunology), Lung (pathology), Lung (virology), Mice, Mice, Inbred C57BL, Orthomyxoviridae Infections (drug therapy), Orthomyxoviridae Infections (immunology), Orthomyxoviridae Infections (pathology), Orthomyxoviridae Infections (virology), PPAR gamma (genetics), PPAR gamma (immunology), Pneumonia (drug therapy), Pneumonia (immunology), Pneumonia (pathology), Pneumonia (virology), Signal Transduction, Tumor Necrosis Factor-alpha (genetics), Tumor Necrosis Factor-alpha (immunology), Viral Load (drug effects), Virus Replication (drug effects).
- MESH :
- chemical , genetics : Chemokine CCL5, Interferon-gamma, Interleukin-1beta, Interleukin-6, PPAR gamma, Tumor Necrosis Factor-alpha.
- chemical , immunology : Chemokine CCL5, Interferon-gamma, Interleukin-1beta, Interleukin-6, PPAR gamma, Tumor Necrosis Factor-alpha.
- chemical , pharmacology : Anti-Inflammatory Agents, Antiviral Agents, Chalcones.
- drug effects : CD8-Positive T-Lymphocytes, Epithelial Cells, Influenza A Virus, H1N1 Subtype, Lung, Viral Load, Virus Replication.
- drug therapy : Orthomyxoviridae Infections, Pneumonia.
- growth & development : Influenza A Virus, H1N1 Subtype.
- immunology : CD8-Positive T-Lymphocytes, Epithelial Cells, Lung, Orthomyxoviridae Infections, Pneumonia.
- pathology : Lung, Orthomyxoviridae Infections, Pneumonia.
- virology : CD8-Positive T-Lymphocytes, Epithelial Cells, Lung, Orthomyxoviridae Infections, Pneumonia.
- Animals, Cell Line, Gene Expression Regulation, Humans, Mice, Mice, Inbred C57BL, Signal Transduction.
Abstract
The host response to influenza virus infection is characterized by an acute lung inflammatory response in which intense inflammatory cell recruitment, hypercytokinemia, and a high level of oxidative stress are present. The sum of these events contributes to the virus-induced lung damage that leads to high a level of morbidity and mortality in susceptible infected patients. In this context, we identified compounds that can simultaneously reduce the excessive inflammatory response and the viral replication as a strategy to treat influenza virus infection. We investigated the anti-inflammatory and antiviral potential activities of isoliquiritigenin (ILG). Interestingly, we demonstrated that ILG is a potent inhibitor of influenza virus replication in human bronchial epithelial cells (50% effective concentration [EC50] = 24.7 μM). In addition, our results showed that this molecule inhibits the expression of inflammatory cytokines induced after the infection of cells with influenza virus. We demonstrated that the anti-inflammatory activity of ILG in the context of influenza virus infection is dependent on the activation of the peroxisome proliferator-activated receptor gamma pathway. Interestingly, ILG phosphate (ILG-p)-treated mice displayed decreased lung inflammation as depicted by reduced cytokine gene expression and inflammatory cell recruitment. We also demonstrated that influenza virus-specific CD8(+) effector T cell recruitment was reduced up to 60% in the lungs of mice treated with ILG-p (10 mg/kg) compared to that in saline-treated mice. Finally, we showed that administration of ILG-p reduced lung viral titers and morbidity of mice infected with the PR8/H1N1 virus.
DOI: 10.1128/AAC.01098-15
PubMed: 26248373
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000408
- to stream PubMed, to step Curation: 000407
- to stream PubMed, to step Checkpoint: 000389
- to stream Ncbi, to step Merge: 000735
- to stream Ncbi, to step Curation: 000735
- to stream Ncbi, to step Checkpoint: 000735
- to stream Main, to step Merge: 000D01
- to stream Main, to step Curation: 000D00
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Flavonoid Isoliquiritigenin Reduces Lung Inflammation and Mouse Morbidity during Influenza Virus Infection.</title><author><name sortKey="Traboulsi, Hussein" sort="Traboulsi, Hussein" uniqKey="Traboulsi H" first="Hussein" last="Traboulsi">Hussein Traboulsi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Pulmonary Division, Faculty of Medicine and Health Sciences, Université de Sherbrooke, and Centre de recherche du CHUS, Sherbrooke, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, Pulmonary Division, Faculty of Medicine and Health Sciences, Université de Sherbrooke, and Centre de recherche du CHUS, Sherbrooke, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Cloutier, Alexandre" sort="Cloutier, Alexandre" uniqKey="Cloutier A" first="Alexandre" last="Cloutier">Alexandre Cloutier</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Pulmonary Division, Faculty of Medicine and Health Sciences, Université de Sherbrooke, and Centre de recherche du CHUS, Sherbrooke, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, Pulmonary Division, Faculty of Medicine and Health Sciences, Université de Sherbrooke, and Centre de recherche du CHUS, Sherbrooke, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Boyapelly, Kumaraswamy" sort="Boyapelly, Kumaraswamy" uniqKey="Boyapelly K" first="Kumaraswamy" last="Boyapelly">Kumaraswamy Boyapelly</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, and Institut de Pharmacologie de Sherbrooke, Sherbooke, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, and Institut de Pharmacologie de Sherbrooke, Sherbooke, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Bonin, Marc Andre" sort="Bonin, Marc Andre" uniqKey="Bonin M" first="Marc-André" last="Bonin">Marc-André Bonin</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, and Institut de Pharmacologie de Sherbrooke, Sherbooke, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, and Institut de Pharmacologie de Sherbrooke, Sherbooke, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Marsault, Eric" sort="Marsault, Eric" uniqKey="Marsault E" first="Éric" last="Marsault">Éric Marsault</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, and Institut de Pharmacologie de Sherbrooke, Sherbooke, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, and Institut de Pharmacologie de Sherbrooke, Sherbooke, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Cantin, Andre M" sort="Cantin, Andre M" uniqKey="Cantin A" first="André M" last="Cantin">André M. Cantin</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Pulmonary Division, Faculty of Medicine and Health Sciences, Université de Sherbrooke, and Centre de recherche du CHUS, Sherbrooke, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, Pulmonary Division, Faculty of Medicine and Health Sciences, Université de Sherbrooke, and Centre de recherche du CHUS, Sherbrooke, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Richter, Martin V" sort="Richter, Martin V" uniqKey="Richter M" first="Martin V" last="Richter">Martin V. Richter</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Pulmonary Division, Faculty of Medicine and Health Sciences, Université de Sherbrooke, and Centre de recherche du CHUS, Sherbrooke, Québec, Canada Martin.Richter@USherbrooke.ca.</nlm:affiliation><country wicri:rule="url">Canada</country><wicri:regionArea>Department of Medicine, Pulmonary Division, Faculty of Medicine and Health Sciences, Université de Sherbrooke, and Centre de recherche du CHUS, Sherbrooke, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26248373</idno><idno type="pmid">26248373</idno><idno type="doi">10.1128/AAC.01098-15</idno><idno type="wicri:Area/PubMed/Corpus">000408</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000408</idno><idno type="wicri:Area/PubMed/Curation">000407</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000407</idno><idno type="wicri:Area/PubMed/Checkpoint">000389</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000389</idno><idno type="wicri:Area/Ncbi/Merge">000735</idno><idno type="wicri:Area/Ncbi/Curation">000735</idno><idno type="wicri:Area/Ncbi/Checkpoint">000735</idno><idno type="wicri:Area/Main/Merge">000D01</idno><idno type="wicri:Area/Main/Curation">000D00</idno><idno type="wicri:Area/Main/Exploration">000D00</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The Flavonoid Isoliquiritigenin Reduces Lung Inflammation and Mouse Morbidity during Influenza Virus Infection.</title><author><name sortKey="Traboulsi, Hussein" sort="Traboulsi, Hussein" uniqKey="Traboulsi H" first="Hussein" last="Traboulsi">Hussein Traboulsi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Pulmonary Division, Faculty of Medicine and Health Sciences, Université de Sherbrooke, and Centre de recherche du CHUS, Sherbrooke, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, Pulmonary Division, Faculty of Medicine and Health Sciences, Université de Sherbrooke, and Centre de recherche du CHUS, Sherbrooke, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Cloutier, Alexandre" sort="Cloutier, Alexandre" uniqKey="Cloutier A" first="Alexandre" last="Cloutier">Alexandre Cloutier</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Pulmonary Division, Faculty of Medicine and Health Sciences, Université de Sherbrooke, and Centre de recherche du CHUS, Sherbrooke, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, Pulmonary Division, Faculty of Medicine and Health Sciences, Université de Sherbrooke, and Centre de recherche du CHUS, Sherbrooke, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Boyapelly, Kumaraswamy" sort="Boyapelly, Kumaraswamy" uniqKey="Boyapelly K" first="Kumaraswamy" last="Boyapelly">Kumaraswamy Boyapelly</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, and Institut de Pharmacologie de Sherbrooke, Sherbooke, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, and Institut de Pharmacologie de Sherbrooke, Sherbooke, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Bonin, Marc Andre" sort="Bonin, Marc Andre" uniqKey="Bonin M" first="Marc-André" last="Bonin">Marc-André Bonin</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, and Institut de Pharmacologie de Sherbrooke, Sherbooke, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, and Institut de Pharmacologie de Sherbrooke, Sherbooke, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Marsault, Eric" sort="Marsault, Eric" uniqKey="Marsault E" first="Éric" last="Marsault">Éric Marsault</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, and Institut de Pharmacologie de Sherbrooke, Sherbooke, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, and Institut de Pharmacologie de Sherbrooke, Sherbooke, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Cantin, Andre M" sort="Cantin, Andre M" uniqKey="Cantin A" first="André M" last="Cantin">André M. Cantin</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Pulmonary Division, Faculty of Medicine and Health Sciences, Université de Sherbrooke, and Centre de recherche du CHUS, Sherbrooke, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, Pulmonary Division, Faculty of Medicine and Health Sciences, Université de Sherbrooke, and Centre de recherche du CHUS, Sherbrooke, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Richter, Martin V" sort="Richter, Martin V" uniqKey="Richter M" first="Martin V" last="Richter">Martin V. Richter</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Pulmonary Division, Faculty of Medicine and Health Sciences, Université de Sherbrooke, and Centre de recherche du CHUS, Sherbrooke, Québec, Canada Martin.Richter@USherbrooke.ca.</nlm:affiliation><country wicri:rule="url">Canada</country><wicri:regionArea>Department of Medicine, Pulmonary Division, Faculty of Medicine and Health Sciences, Université de Sherbrooke, and Centre de recherche du CHUS, Sherbrooke, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author></analytic><series><title level="j">Antimicrobial agents and chemotherapy</title><idno type="eISSN">1098-6596</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Anti-Inflammatory Agents (pharmacology)</term><term>Antiviral Agents (pharmacology)</term><term>CD8-Positive T-Lymphocytes (drug effects)</term><term>CD8-Positive T-Lymphocytes (immunology)</term><term>CD8-Positive T-Lymphocytes (virology)</term><term>Cell Line</term><term>Chalcones (pharmacology)</term><term>Chemokine CCL5 (genetics)</term><term>Chemokine CCL5 (immunology)</term><term>Epithelial Cells (drug effects)</term><term>Epithelial Cells (immunology)</term><term>Epithelial Cells (virology)</term><term>Gene Expression Regulation</term><term>Humans</term><term>Influenza A Virus, H1N1 Subtype (drug effects)</term><term>Influenza A Virus, H1N1 Subtype (growth & development)</term><term>Interferon-gamma (genetics)</term><term>Interferon-gamma (immunology)</term><term>Interleukin-1beta (genetics)</term><term>Interleukin-1beta (immunology)</term><term>Interleukin-6 (genetics)</term><term>Interleukin-6 (immunology)</term><term>Lung (drug effects)</term><term>Lung (immunology)</term><term>Lung (pathology)</term><term>Lung (virology)</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Orthomyxoviridae Infections (drug therapy)</term><term>Orthomyxoviridae Infections (immunology)</term><term>Orthomyxoviridae Infections (pathology)</term><term>Orthomyxoviridae Infections (virology)</term><term>PPAR gamma (genetics)</term><term>PPAR gamma (immunology)</term><term>Pneumonia (drug therapy)</term><term>Pneumonia (immunology)</term><term>Pneumonia (pathology)</term><term>Pneumonia (virology)</term><term>Signal Transduction</term><term>Tumor Necrosis Factor-alpha (genetics)</term><term>Tumor Necrosis Factor-alpha (immunology)</term><term>Viral Load (drug effects)</term><term>Virus Replication (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anti-inflammatoires (pharmacologie)</term><term>Antiviraux (pharmacologie)</term><term>Cellules épithéliales ()</term><term>Cellules épithéliales (immunologie)</term><term>Cellules épithéliales (virologie)</term><term>Chalcones (pharmacologie)</term><term>Charge virale ()</term><term>Chimiokine CCL5 (génétique)</term><term>Chimiokine CCL5 (immunologie)</term><term>Facteur de nécrose tumorale alpha (génétique)</term><term>Facteur de nécrose tumorale alpha (immunologie)</term><term>Humains</term><term>Infections à Orthomyxoviridae (anatomopathologie)</term><term>Infections à Orthomyxoviridae (immunologie)</term><term>Infections à Orthomyxoviridae (traitement médicamenteux)</term><term>Infections à Orthomyxoviridae (virologie)</term><term>Interféron gamma (génétique)</term><term>Interféron gamma (immunologie)</term><term>Interleukine-1 bêta (génétique)</term><term>Interleukine-1 bêta (immunologie)</term><term>Interleukine-6 (génétique)</term><term>Interleukine-6 (immunologie)</term><term>Lignée cellulaire</term><term>Lymphocytes T CD8+ ()</term><term>Lymphocytes T CD8+ (immunologie)</term><term>Lymphocytes T CD8+ (virologie)</term><term>Pneumopathie infectieuse (anatomopathologie)</term><term>Pneumopathie infectieuse (immunologie)</term><term>Pneumopathie infectieuse (traitement médicamenteux)</term><term>Pneumopathie infectieuse (virologie)</term><term>Poumon ()</term><term>Poumon (anatomopathologie)</term><term>Poumon (immunologie)</term><term>Poumon (virologie)</term><term>Récepteur PPAR gamma (génétique)</term><term>Récepteur PPAR gamma (immunologie)</term><term>Régulation de l'expression des gènes</term><term>Réplication virale ()</term><term>Souris</term><term>Souris de lignée C57BL</term><term>Sous-type H1N1 du virus de la grippe A ()</term><term>Sous-type H1N1 du virus de la grippe A (croissance et développement)</term><term>Transduction du signal</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Chemokine CCL5</term><term>Interferon-gamma</term><term>Interleukin-1beta</term><term>Interleukin-6</term><term>PPAR gamma</term><term>Tumor Necrosis Factor-alpha</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Chemokine CCL5</term><term>Interferon-gamma</term><term>Interleukin-1beta</term><term>Interleukin-6</term><term>PPAR gamma</term><term>Tumor Necrosis Factor-alpha</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-Inflammatory Agents</term><term>Antiviral Agents</term><term>Chalcones</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Infections à Orthomyxoviridae</term><term>Pneumopathie infectieuse</term><term>Poumon</term></keywords><keywords scheme="MESH" qualifier="croissance et développement" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>CD8-Positive T-Lymphocytes</term><term>Epithelial Cells</term><term>Influenza A Virus, H1N1 Subtype</term><term>Lung</term><term>Viral Load</term><term>Virus Replication</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Orthomyxoviridae Infections</term><term>Pneumonia</term></keywords><keywords scheme="MESH" qualifier="growth & development" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Chimiokine CCL5</term><term>Facteur de nécrose tumorale alpha</term><term>Interféron gamma</term><term>Interleukine-1 bêta</term><term>Interleukine-6</term><term>Récepteur PPAR gamma</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Cellules épithéliales</term><term>Chimiokine CCL5</term><term>Facteur de nécrose tumorale alpha</term><term>Infections à Orthomyxoviridae</term><term>Interféron gamma</term><term>Interleukine-1 bêta</term><term>Interleukine-6</term><term>Lymphocytes T CD8+</term><term>Pneumopathie infectieuse</term><term>Poumon</term><term>Récepteur PPAR gamma</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>CD8-Positive T-Lymphocytes</term><term>Epithelial Cells</term><term>Lung</term><term>Orthomyxoviridae Infections</term><term>Pneumonia</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lung</term><term>Orthomyxoviridae Infections</term><term>Pneumonia</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Anti-inflammatoires</term><term>Antiviraux</term><term>Chalcones</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à Orthomyxoviridae</term><term>Pneumopathie infectieuse</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Cellules épithéliales</term><term>Infections à Orthomyxoviridae</term><term>Lymphocytes T CD8+</term><term>Pneumopathie infectieuse</term><term>Poumon</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>CD8-Positive T-Lymphocytes</term><term>Epithelial Cells</term><term>Lung</term><term>Orthomyxoviridae Infections</term><term>Pneumonia</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cell Line</term><term>Gene Expression Regulation</term><term>Humans</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Signal Transduction</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Cellules épithéliales</term><term>Charge virale</term><term>Humains</term><term>Lignée cellulaire</term><term>Lymphocytes T CD8+</term><term>Poumon</term><term>Régulation de l'expression des gènes</term><term>Réplication virale</term><term>Souris</term><term>Souris de lignée C57BL</term><term>Sous-type H1N1 du virus de la grippe A</term><term>Transduction du signal</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The host response to influenza virus infection is characterized by an acute lung inflammatory response in which intense inflammatory cell recruitment, hypercytokinemia, and a high level of oxidative stress are present. The sum of these events contributes to the virus-induced lung damage that leads to high a level of morbidity and mortality in susceptible infected patients. In this context, we identified compounds that can simultaneously reduce the excessive inflammatory response and the viral replication as a strategy to treat influenza virus infection. We investigated the anti-inflammatory and antiviral potential activities of isoliquiritigenin (ILG). Interestingly, we demonstrated that ILG is a potent inhibitor of influenza virus replication in human bronchial epithelial cells (50% effective concentration [EC50] = 24.7 μM). In addition, our results showed that this molecule inhibits the expression of inflammatory cytokines induced after the infection of cells with influenza virus. We demonstrated that the anti-inflammatory activity of ILG in the context of influenza virus infection is dependent on the activation of the peroxisome proliferator-activated receptor gamma pathway. Interestingly, ILG phosphate (ILG-p)-treated mice displayed decreased lung inflammation as depicted by reduced cytokine gene expression and inflammatory cell recruitment. We also demonstrated that influenza virus-specific CD8(+) effector T cell recruitment was reduced up to 60% in the lungs of mice treated with ILG-p (10 mg/kg) compared to that in saline-treated mice. Finally, we showed that administration of ILG-p reduced lung viral titers and morbidity of mice infected with the PR8/H1N1 virus. </div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Traboulsi, Hussein" sort="Traboulsi, Hussein" uniqKey="Traboulsi H" first="Hussein" last="Traboulsi">Hussein Traboulsi</name></noRegion><name sortKey="Bonin, Marc Andre" sort="Bonin, Marc Andre" uniqKey="Bonin M" first="Marc-André" last="Bonin">Marc-André Bonin</name><name sortKey="Boyapelly, Kumaraswamy" sort="Boyapelly, Kumaraswamy" uniqKey="Boyapelly K" first="Kumaraswamy" last="Boyapelly">Kumaraswamy Boyapelly</name><name sortKey="Cantin, Andre M" sort="Cantin, Andre M" uniqKey="Cantin A" first="André M" last="Cantin">André M. Cantin</name><name sortKey="Cloutier, Alexandre" sort="Cloutier, Alexandre" uniqKey="Cloutier A" first="Alexandre" last="Cloutier">Alexandre Cloutier</name><name sortKey="Marsault, Eric" sort="Marsault, Eric" uniqKey="Marsault E" first="Éric" last="Marsault">Éric Marsault</name><name sortKey="Richter, Martin V" sort="Richter, Martin V" uniqKey="Richter M" first="Martin V" last="Richter">Martin V. Richter</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D00 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000D00 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= StressCovidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26248373
|texte= The Flavonoid Isoliquiritigenin Reduces Lung Inflammation and Mouse Morbidity during Influenza Virus Infection.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26248373" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a StressCovidV1
| This area was generated with Dilib version V0.6.33. |  |